Clinical Trials
53 trialsCabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
University of California, San Diego
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
M.D. Anderson Cancer Center
CABOTHYROID
Grupo Espanol de Tumores Neuroendocrinos
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
University of California, Irvine
ZEBRA
Istituto Oncologico Veneto IRCCS
Cabozantinib and Pembrolizumab in Metastatic Pancreas
University of Kentucky
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
Washington University School of Medicine
UNICAB
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
CABRAMET
Centre Leon Berard
Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Massachusetts General Hospital
ACTION
Fundacion Clinic per a la Recerca Biomédica
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
University of Colorado, Denver
Cabozantinib and Nivolumab for Carcinoid Tumors
Dana-Farber Cancer Institute
Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
CaPture
University of Leipzig
Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital
NICARAGUA
Fundacion CRIS de Investigación para Vencer el Cáncer
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
M.D. Anderson Cancer Center
PemCab
University of Utah
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MERIDIAN
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Memorial Sloan Kettering Cancer Center
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
University of Utah
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Dana-Farber Cancer Institute
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
M.D. Anderson Cancer Center
CABOMAYOR
Spanish Oncology Genito-Urinary Group
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
NF105-CABO
University of Alabama at Birmingham
Cabozantinib With Topotecan-Cyclophosphamide
Dana-Farber Cancer Institute
CABOCOL-01
Centre Francois Baclesse
SRWEC
Spanish Oncology Genito-Urinary Group
Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
University of Colorado, Denver
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
M.D. Anderson Cancer Center
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
Dana-Farber Cancer Institute
XL-184+Abiraterone in Post-Chemo CRPC
Dana-Farber Cancer Institute
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases
Dana-Farber Cancer Institute
BONSAI
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
BREAKPOINT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
CaboMAb
Duke University
Cabozantinib in Advanced Solid Malignancies
Massachusetts General Hospital
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
University of Chicago
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
University of Michigan Rogel Cancer Center
A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Cedars-Sinai Medical Center
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Memorial Sloan Kettering Cancer Center
Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Massachusetts General Hospital
XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease
Massachusetts General Hospital